These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 20030566

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
    Croom KF, Curran MP, Goa KL, Perry CM.
    Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
    [Abstract] [Full Text] [Related]

  • 5. The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review.
    Borghi C, Cicero AF.
    High Blood Press Cardiovasc Prev; 2012 Mar 01; 19(1):19-31. PubMed ID: 22670584
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M, Bienfait-Beuzon C, Jackson J.
    J Hum Hypertens; 2008 Dec 01; 22(12):845-55. PubMed ID: 18633426
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Bilous RW.
    J Hum Hypertens; 2004 Oct 01; 18(10):733-8. PubMed ID: 15116142
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Ruilope LM, Segura J.
    Clin Ther; 2003 Dec 01; 25(12):3044-64. PubMed ID: 14749145
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
    Belsey JD.
    Curr Med Res Opin; 2008 Feb 01; 24(2):581-9. PubMed ID: 18198012
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
    Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH.
    Diabetes Care; 2004 Aug 01; 27(8):1897-903. PubMed ID: 15277414
    [Abstract] [Full Text] [Related]

  • 18. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
    Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M.
    Curr Med Res Opin; 2006 Nov 01; 22(11):2095-100. PubMed ID: 17076969
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
    Palmer AJ, Roze S, Valentine WJ, Ray JA, Frei A, Burnier M, Hess B, Spinas GA, Brändle M.
    Swiss Med Wkly; 2006 May 27; 136(21-22):346-52. PubMed ID: 16779715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.